The Trend of Procuring Online Education Intervention Solutions

 

Education systems that have taken a metered approach towards spending for instruction materials are also using this methodology to procure online education intervention solutions.

Estimates put the overall global Online Tutoring Market at 6.52 Billion in 2021, and experts believe that number could reach over 19 Billion a year by 2030.

And while online education intervention solutions provide much-needed services, Doug Roberts, Founder and CEO of The Institute for Education Innovation, wonders if this practice will stick once education pandemic relief funds wind down.

Doug’s Thoughts

“Here’s a trend I’m seeing. This trend is the first time I’ve seen a business model for procuring a product talking specifically about the purchasing procurement model, change so dramatically. We’re seeing a ton of districts choose to go with a metered spending approach on intervention solutions, particularly solutions involving live tutors, virtual tutors, onsite tutors, and sometimes intervention by text messaging back and forth between kids and tutors, or live video tutoring.

You’re seeing districts really shift how they purchase instructional materials in this way. It’s a new model that has come up through the pandemic as a way to address so-called learning and to address the gaps that show up between various kids and in many cases, to address gaps related to equity, the kind of resources available to kids in some districts versus others.

You’re seeing districts adopt these solutions en masse. What will happen when the fiscal cliff comes in 2024, the fall of 2024? How many of these solutions will survive? How many of these districts will continue to do this kind of work? Or will they go back to the type of annual license model?

That’s an innovation that I’m watching. And here at IEI, we run the Supes’ Choice Awards to get some of the best district leaders in the country to review these solutions, innovations, and models and provide industry feedback about which will be most effective for kids.

You can learn more about Supes’ Choice at supeschoice.com. We start taking applications in the summer of 2023.”

Article by James Kent

 

 

 

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More